Summary Kyorin Pharmaceutical Co Ltd (Kyorin), a subsidiary of Kyorin Holdings Inc, is a pharmaceutical company that manufactures and markets prescription medicines.The company offers ethical drugs including mucodyne, kipres, desalex, flutiform, pentasa, ketas and uritos.
Its ketas product is a phosphodiesterase inhibitor agent for ameliorating bronchial asthma and cerebro-vascular disorders.Kyorin’s kipres is a bronchial asthma and allergic rhinitis therapeutic drug; and pentasa is an agent for ulcerative colitis and chrohn’s disease.
It offers consumer healthcare products such as milton and milton CP and OTC drugs.The company collaborates with other companies to develop new medicine.
It has operations in the US and Germany. Kyorin is headquartered in Tokyo, Japan.
Kyorin Pharmaceutical Co Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings.The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period.
The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope - Financial Deals - Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. - Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. - Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. - Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. - Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector. - Major Deals - Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios. - Business Description - A brief description of the company’s operations. - Key Employees - A list of the key executives of the company. - Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company. - Key Competitors - A list of the key competitors of the company. - Key Recent Developments - A brief on recent news about the company.
Reasons to Buy Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements - The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy - The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company - Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers. - The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company - Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research - Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Our reports have been used by over 10K customers, including:
The Amyotrophic Lateral Sclerosis Treatment is expected to register a CAGR of 5.5% during the forecast period. This is attributing the rising prevalence of amyotrophic lateral sclerosis diseases and the growing geriatric population worldwide. As per the Centers for Disease Control and Prevention, in 2016, amyotrophic lateral sclerosis (ALS)...
Insulin Like Growth Factor I - Pipeline Review, H2 2020 Summary Insulin Like Growth Factor I (Mechano Growth Factor or Somatomedin C or IGF1) - Insulin-like growth factor 1 (IGF-1) also called somatomedin C is a protein encoded by the IGF1 gene. It stimulates glucose transport in bone-derived osteoblastic...
Insulin Like Growth Factor II - Pipeline Review, H2 2020 Summary According to the recently published report ’Insulin Like Growth Factor II - Pipeline Review, H2 2020’; Insulin Like Growth Factor II (Somatomedin A or T3M 11 Derived Growth Factor or IGF2) pipeline Target constitutes close to 7 molecules....
Cardiac Marker Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Cardiac Marker Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Cardiac Marker Tests pipeline products with comparative analysis of the products...
‘AL Amyloidosis – Epidemiology Forecast—2030’ report delivers an in-depth understanding of the AL Amyloidosis, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan. AL Amyloidosis Disease Understanding Amyloidosis refers to a group of...
Inborn Gene or Chromosome Alterations Tests - Medical Devices Pipeline Assessment, 2020 Summary Medical Devices sector report, “Inborn Gene or Chromosome Alterations Tests - Medical Devices Pipeline Assessment, 2020" provides comprehensive information about the Inborn Gene or Chromosome Alterations...
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.